

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/735,594
Filing Date	December 12, 2003
First Named Inventor	Charles L. Brooks
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	18525/04051

Total Number of Pages in This Submission

### ENCLOSURES (Check all that apply)

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance communication to Technology Center (TC)<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Remarks

Return receipt postcard

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm --  
or  
Individual name

Sean C. Myers-Payne  
Reg. No. 42,920

Signature

*Sean Myers-Payne*

Date

April 12, 2004

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Janet L. Norris

Signature

*Janet L. Norris*


Date

April 12, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08A (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Date for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/735,594
Filing Date	December 12, 2003
First Named Inventor	Charles L. Brooks
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	18525/04051

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KUNKEL, T.A., "Rapid and efficient site-specific mutagenesis without phenotypic selection", <u>Proc. Natl. Acad. Sci. USA</u> , January 1985, Volume 82, Pages 488-492.	
		KUNKEL et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection", <u>Methods in Enzymology</u> , Volume 154, Pages 367-382.	
		DUDA et al., "Human growth hormone site 2 lactogenic activity requires a distant tyrosine164", <u>FEBS Letters</u> , 1999, Volume 449, Pages 120-124.	
		KUNKEL et al., "Efficient Site-Directed Mutagenesis using Uracil-Containing DNA", <u>Methods in Enzymology</u> , 1991, Volume 204, Pages 125-139.	
		PETERSON et al., "Identification of a Motif Associated with the Lactogenic Actions of Human Growth Hormone", <u>The Journal of Biological Chemistry</u> , 1997, Volume 272, Issue 34, Pages 21444-21448.	
		PETERSON et al., "Expression, Folding, and Characterization of Small Proteins with Increasing Disulfide Complexity by a pT7-7-Derived Phagemid", <u>Protein Expression and Purification</u> , 1999, Volume 15, Pages 16-23.	
		MUNSON et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems", <u>Analytical Biochemistry</u> , 1980, Volume 107, Pages 220-239.	
		CHANTALAT et al., "The Crystal Structure of Wild-Type Growth Hormone at 2.5 Å Resolution", <u>Protein and Peptide Letters</u> , 1995, Volume 2, Number 2, Pages 333-340.	
		SOMERS et al., "The X-ray structure of a growth hormone-prolactin receptor complex", <u>Letters To Nature</u> , December 1, 1994, Volume 372, Pages 478-481.	
		DUDA et al., "Identification of Residues Outside the Two Binding Sites That Are Critical for Activation of the Lactogenic Activity of Human Growth Hormone", <u>The Journal of Biological Chemistry</u> , 2003, Volume 278, Number 25, Pages 22734-22739.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/735,594
Filing Date	December 12, 2003
First Named Inventor	Charles L. Brooks
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	18525/04051

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KEELER et al., "The Tertiary Structure and Backbone Dynamics of Human Prolactin", <u>Journal of Molecular Biology</u> , 2003, Volume 328, Pages 1105-1121.	
		ELKINS et al., "Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor", <u>Nature Structural Biology</u> , Volume 7, Number 9, Pages 808-815.	
		MATERA et al., "Prolactin is an autocrine growth factor for the Hurkat human T-leukemic cell line", <u>Journal of Neuroimmunology</u> , 1997, Volume 79, Pages 12-21.	
		BERNICHTEN et al., "Development of Pure Prolactin Receptor Antagonists", <u>The Journal of Biological Chemistry</u> , 2003, Volume 278, Number 38, Pages 35988-35999.	
		BOLE-FEYSOT et al., "Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice", <u>Endocrine Reviews</u> , 1998, Volume 19, Number 3, Pages 225-268.	
		CLEVENGER et al., "Prolactin receptor signal transduction in cells of the immune system", <u>Journal of Endocrinology</u> , 1998, Volume 157, Pages 187-197.	
		WELLS, James A., "Binding in the growth hormone receptor complex", <u>Proc. Natl. Acad. Sci. USA</u> , January 1996, Volume 93, Pages 1-6.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.